Divarasib

N/A

Report date: 2026/04/22 20:01:10
NME

Base Information

Drug NameDivarasib
Drug Alias NameRG-6330GDC-6036RO-7435846
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12C inhibitors
TargetsKRAS G12C
Therapy Area/IndicationsSolid tumoursHepatic InsufficiencyCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[36] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharmaceutical Co LtdF. Hoffmann-La Roche AgF. Hoffmann-La Roche Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursHepatic InsufficiencyCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A